All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Tessa Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Singapore

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

Tessa gets RMAT designation for new CAR-T

Contact the Supplier

Lead Product(s): CD30 CAR-T

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

The designation is based on the data of two independent Phase I/II trials, which show promising efficacy and strong safety profile of the therapy in Hodgkin lymphoma patients.